1 / 16

ICAAC 2005

Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy and Suppressed HIV RNA on HAART The RAVE Study. G Moyle 1 , C Sabin 2 , J Cartledge 3 , M Johnson 2 , E Wilkins 4 , D Churchill 5 ,

Jeffrey
Download Presentation

ICAAC 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Changes in Lipids in Randomised, Open-Label Comparative Trial of Abacavir or Tenofovir DF as Replacement for a Thymidine Analogue in Persons with Lipoatrophy and Suppressed HIV RNA on HAART The RAVE Study G Moyle1 , C Sabin2, J Cartledge3, M Johnson2, E Wilkins4, D Churchill5 , P Hay6, A Fakoya7, M Murphy8, G Scullard9, C Leen10, G Reilly11 for the RAVE study group UK 1 Chelsea and Westminster Hosp, London, 2 Royal Free & UC Medical School, London, 3 UCL London, 4 North Manchester Hosp, 5 Lawson Unit Royal Sussex County Hosp, 6 St Georges Hosp London, 7 Newham General London, 8 St Barts & The London, 9 St Mary’s Hosp London, 10 Western General Hosp Edinburgh, 11 Gilead Sciences UK ICAAC 2005

  2. RAVERationale • Thymidine analogue therapy is associated with peripheral fat loss and dyslipidemia • Duration of exposure to HAART has been associated with increased risk of CV disease. This may, in part, be mediated through ART-associated dyslipidemia • In initial treatment regimens tenofovir is associated with smaller changes in total cholesterol and triglycerides than either d4T or AZT • The lipid profile of abacavir relative to thymidine analogues has not been well characterised Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  3. RAVEDesign 48 wks TDF QD + NRTI + PI, PI/r or NNRTI Thymidine analogue recipients (n = 105) randomised 1:1 Moderate-Severe Lipoatrophy Any CD4 cell count HIV RNA <50 c/mL Stable ARV Therapy for >24 weeks 48 wks ABC BD + NRTI + PI, PI/r or NNRTI No history of TDF or ABC use or resistance Adequate Renal and Hepatic Function at baseline Moyle 12th CROI 2005: 44LB

  4. RAVEStatistical Methods • Trial endpoints: change in total limb fat mass (by DEXA) and lipids from baseline to 48 weeks • Changes in lipids were approximately normally distributed • Changes in values over 48 weeks were tested for significance using paired t-tests; the changes in the two treatment groups were compared using unpaired t-tests • Analyses of changes in lipids were based on all values as measured, disregarding any information on the use of lipid-lowering therapy • All analyses were performed on an intention-to-treat basis.  Missing values were imputed using a last-observation-carried-forward approach Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  5. RAVEBaseline Characteristics Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  6. RAVEBaseline Median Metabolics Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  7. RAVEPatient Disposition through Week 48 * All discontinuations due to adverse events in ABC group were due to hypersensitivity reaction, TDF related discontinuation was secondary to diarrhoea Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  8. RAVEMedianChange in Limb FatDEXA arm fat + total leg fat in grams (ITT m=f analysis) Median Baseline Limb Fat TDF 3.0kg, ABC 2.9kg p=0.97 Moyle 12th CROI 2005: 44LB

  9. RAVEMedian changes at week 48 in Limb Fat by DEXA by baseline characteristics Median Baseline Limb Fat 3.0kg 2.9kg 5.12kg 2.97kg 2.91kg 2.74kg p=0.97 Change in fat mass (g) by DEXA n: 49 44 12 16 37 28 31 32 18 12 Moyle 12th CROI 2005: 44LB

  10. RAVEMean Change in Metabolic Outcomes to Week 48 Lactate Total Cholesterol HDL Cholesterol LDL Cholesterol Triglycerides P=0.003 P=0.04 P=0.34 P=0.12 P=0.71 All individuals included. Lipid lowering therapy commenced during study for TDF n=1, at 273 days , ABC n=8, at median 91.5days Includes fasting and non-fasting samples. Observations are similar when only fasting samples are included Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340 *P values by paired t- test

  11. RAVEChanges in Mean Fasting Cholesterol (mmol/l) by baseline Thymidine analog d4T at Baseline AZT at Baseline Fasting Cholesterol (mmol/l) Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  12. RAVEChanges in Mean Fasting LDL-c (mmol/l) by baseline thymidine analogue d4T at Baseline AZT at Baseline Fasting Cholesterol (mmol/l) Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  13. RAVEChanges in Mean Fasting HDL-c (mmol/l) by baseline Thymidine analogue d4T at Baseline AZT at Baseline Fasting Cholesterol (mmol/l) Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  14. RAVEChanges in Mean Fasting Triglycerides (mmol/l) by baseline Thymidine analogue d4T at Baseline AZT at Baseline Fasting Cholesterol (mmol/l) All data LOCF. All individuals included. Lipid lowering therapy commenced during study for TDF n=1, at 273 days , ABC n=8, at median 91.5daysIncludes fasting and non-fasting samples. Observations are similar when only fasting samples are included Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  15. RAVE: % patients with dyslipidemia* at baseline and week 48 by randomized group HDL Cholesterol <0.9mmol/l or 35mg/dl Total Cholesterol >6.2mmol/l or 240mg/dl LDL Cholesterol >4.1mmol/l or 160mg/dl Triglycerides <2.3mmol/l or 200mg/dl P=0.24 P=1.00 P=1.00 P=1.00 Baseline Baseline Week 48 Week 48 Baseline Baseline Week 48 Week 48 * NCEP ATPIII Category ‘high’ Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

  16. RAVESummary • TDF and ABC similarly allow restoration of limb fat over 48 weeks when switching from thymidine analogues in persons with lipoatrophy • Lipid changes favored the TDF arm. Fewer TDF patients initiated lipid lowering therapy • Baseline lipids were generally higher in the d4T arm • Falls in total cholesterol and TGs were predominately seen in individuals on d4T at baseline Moyle et al. 45th ICAAC Sept 21-24, 2005: abstract H-340

More Related